Zymo Consulting Group
Zymo comes from ‘enzyme’, a type of protein that catalyzes biological reactions; that is, it speeds them up.
The average time from target identification to drug approval is 13 years, and costs may exceed $1 billion.*
* Collins, F. S. (2011). "Reengineering translational science: the time is right." Sci Transl Med 3(90): 90cm17.
Zymo’s experience in clinical development, strategy, and regulatory affairs can keep your company on track, whether you are a startup thinking about your first IND, a larger company that needs hands-on expertise to advance a project, or an investor trying to evaluate the likelihood that a biopharma company can meet its goals.
Catalyze Your Drug Development
Clinical Research & Development
Plan first, implement second. The development of well-written and innovative protocols can accelerate development programs and reduce regulatory overhead. Nimble clinical leadership keeps your program responsive to changing demands
Regulatory
Getting regulators to understand your needs is essential to success. Briefing documents need to be clear, questions direct, and to the point.
Strategy
Success means having more than an innovative drug and a great team. It needs planning: planning your trials, your interactions with key opinion leaders, your publications. But no plan is ever cast in stone!
Clinical
– Services
Clinical Hold Averted
– Case Study